Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wiernasz

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Frontiers in Microbiology|February 11, 2020
Salmon Gravlax Biopreservation With Lactic Acid Bacteria: A Polyphasic Approach to Assessing the Impact on Organoleptic Properties, Microbial Ecosystem and Volatilome CompositionNorman Wiernasz, Françoise Leroi, Frédérique Chevalier, et al.
Foods (Basel, Switzerland)|November 27, 2021
Effect of the Manufacturing Process on the Microbiota, Organoleptic Properties and Volatilome of Three Salmon-Based ProductsNorman Wiernasz, Frédérique Gigout, Mireille Cardinal, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2004
Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccineElizabeth M H Woodson, Kimberly A Chianese-Bullock, Catherine J Wiernasz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomesC L Slingluff, G Yamshchikov, P Neese, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2004
Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed scheduleCraig L Slingluff, Gina R Petroni, Galina V Yamshchikov, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 25, 2005
MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanomaKimberly A Chianese-Bullock, Jennifer Pressley, Courtney Garbee, et al.
The Journal of Cell Biology|May 20, 2009
Heterochromatin protein 1 is recruited to various types of DNA damageMartijn S Luijsterburg, Christoffel Dinant, Hannes Lans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cellsCraig L Slingluff, Gina R Petroni, Galina V Yamshchikov, et al.
Nature|March 25, 2011
Inclusive fitness theory and eusocialityPatrick Abbot, Jun Abe, John Alcock, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Frontiers in Microbiology|February 11, 2020
Salmon Gravlax Biopreservation With Lactic Acid Bacteria: A Polyphasic Approach to Assessing the Impact on Organoleptic Properties, Microbial Ecosystem and Volatilome CompositionNorman Wiernasz, Françoise Leroi, Frédérique Chevalier, et al.
Foods (Basel, Switzerland)|November 27, 2021
Effect of the Manufacturing Process on the Microbiota, Organoleptic Properties and Volatilome of Three Salmon-Based ProductsNorman Wiernasz, Frédérique Gigout, Mireille Cardinal, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2004
Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccineElizabeth M H Woodson, Kimberly A Chianese-Bullock, Catherine J Wiernasz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomesC L Slingluff, G Yamshchikov, P Neese, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2004
Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed scheduleCraig L Slingluff, Gina R Petroni, Galina V Yamshchikov, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 25, 2005
MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanomaKimberly A Chianese-Bullock, Jennifer Pressley, Courtney Garbee, et al.
The Journal of Cell Biology|May 20, 2009
Heterochromatin protein 1 is recruited to various types of DNA damageMartijn S Luijsterburg, Christoffel Dinant, Hannes Lans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cellsCraig L Slingluff, Gina R Petroni, Galina V Yamshchikov, et al.
Nature|March 25, 2011
Inclusive fitness theory and eusocialityPatrick Abbot, Jun Abe, John Alcock, et al.
Pageof 3